GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q2 FY24 results · Jul–Sep 2023
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹956.99 crore (up 4.4% from Q2 FY23) and net profit of ₹217.51 crore (up 12.5% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 956.99 | 916.87 | +4.4% | 761.66 | +25.6% |
| Other income | 28.21 | 21.97 | +28.4% | 36.44 | −22.6% |
| Total income | 985.20 | 938.84 | +4.9% | 798.10 | +23.4% |
| Profit before tax | 299.16 | 262.15 | +14.1% | 180.98 | +65.3% |
| Net profit for the period | 217.51 | 193.42 | +12.5% | 132.25 | +64.5% |
| EPS, basic (₹) | 12.84 | 11.42 | +12.4% | 7.04 | +82.4% |
| Net margin (%) | 22.7 | 21.1 | 17.4 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 953.38 | 905.61 | +5.3% | 738.02 | +29.2% |
| Other income | 28.47 | 22.16 | +28.5% | 36.80 | −22.6% |
| Total income | 981.85 | 927.77 | +5.8% | 774.82 | +26.7% |
| Profit before tax | 296.51 | 262.33 | +13.0% | 178.71 | +65.9% |
| Net profit for the period | 215.54 | 193.56 | +11.4% | 130.58 | +65.1% |
| EPS, basic (₹) | 12.72 | 11.42 | +11.4% | 6.94 | +83.3% |
| Net margin (%) | 22.6 | 21.4 | 17.7 |
Consolidated
- Filed with BSE
- 13 Nov 2023, 15:28 IST
- Board meeting
- 09 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2023, 15:28 IST
- Board meeting
- 09 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE